Ketoconazole
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Ketoconazole: From Fungal Infections to Acne (Disease)
One-Sentence Summary
Ketoconazole is an imidazole antifungal agent originally developed to treat fungal infections. The TxGNN model predicts it may also be effective for Acne (Disease), with 1 clinical trial and 15 publications currently supporting this direction, most of which are preclinical/mechanistic in nature.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Fungal infections (imidazole antifungal class) |
| Predicted New Indication | Acne (Disease) |
| TxGNN Prediction Score | 99.80% |
| Evidence Level | L4 |
| Germany Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action (MOA) data for ketoconazole is not available in this evidence pack. Based on known pharmacology, ketoconazole belongs to the imidazole antifungal class, and its efficacy in treating fungal infections is well established.
The literature evidence, however, points to a plausible mechanistic bridge to acne: ketoconazole has been shown in vitro to inhibit the lipase activity of Propionibacterium (Cutibacterium) acnes (PMID 28111792), the bacterium implicated in acne pathogenesis, and other azole antifungals show similar anti-P. acnes activity (PMID 20045949). Since sebum-metabolizing lipase activity drives the inflammatory cascade in acne, an agent that suppresses this enzyme — independent of its antifungal action — could plausibly reduce acne severity. This mechanistic rationale is consistent with the drug now being tested clinically as a topical alternative to retinoids for mild acne (NCT07237763).
Several literature entries in this pack (e.g., neonatal Malassezia/Pityrosporum folliculitis misdiagnosed as acne) further illustrate ketoconazole's established role in treating fungal-driven pustular skin conditions that clinically overlap with acne presentations, lending indirect support to repurposing.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07237763 | NA | Active, not recruiting | 52 | RCT comparing topical ketoconazole 2% cream vs. topical adapalene 2% cream in mild comedonal/papulopustular acne, assessing whether ketoconazole is a viable alternative to retinoids with better tolerability |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28111792 | 2017 | In vitro study | Microbiol Immunol | Ketoconazole inhibits P. acnes lipase activity, suggesting a potential alternative acne treatment mechanism beyond antifungal action |
| 20045949 | 2010 | In vitro study | Biol Pharm Bull | Azole antifungals, including ketoconazole, show in vitro activity against P. acnes isolated from acne vulgaris patients |
| 12566804 | 2003 | Review | Dermatology (Basel) | Overview of systemic acne treatments; discusses antibiotic resistance issues driving interest in alternative anti-bacterial agents |
| 32872149 | 2020 | Review | Pharmaceuticals (Basel) | Reviews adapalene (the trial comparator) as first-line acne therapy, contextualizing ketoconazole's proposed role as an alternative |
| 39622522 | 2024 | Retrospective study | South Med J | Analysis of dermatology formulary use patterns, including antifungal/acne agents, in a free clinic setting |
| 8629828 | 1996 | Case report | Arch Dermatol | Neonatal Malassezia furfur pustulosis, a condition clinically overlapping with neonatal acne, linked to fungal pathogenesis |
| 23600337 | 2013 | Review | FP Essentials | Reviews common infant skin rashes including neonatal/infantile acne and their differential diagnosis from fungal folliculitis |
| 8593718 | 1995 | Case series | Clin Exp Dermatol | Pityrosporum folliculitis frequently misdiagnosed as acne vulgaris; responds to antifungal (azole) therapy |
| 8255067 | 1993 | Review | Keio J Med | Pityrosporum ovale implicated in multiple skin conditions with clinical overlap to acne-type eruptions |
| 19445767 | 2009 | Review | BMJ Clin Evid | PCOS review noting acne as an androgen-driven symptom, relevant to ketoconazole's known anti-androgenic properties |
Germany Market Information
This drug currently has no marketing authorizations recorded in Germany (market status: not marketed, 0 licenses on file).
Safety Considerations
Please refer to the package insert for safety information. Detailed TFDA/BfArM warnings, contraindications, and drug-drug interaction data are not yet available in this evidence pack (flagged as a Blocking data gap — DG001).
Conclusion and Next Steps
Decision: Hold
Rationale: A blocking data gap exists — TFDA/BfArM label warnings and contraindications are unavailable, which prevents completion of the S1 safety pre-assessment. Clinical evidence is also limited to a single ongoing Phase NA trial, with most supporting literature being in vitro or mechanistic rather than confirmatory clinical studies.
To proceed, the following is needed:
- Obtain official package insert / label data (warnings, contraindications) from TFDA or BfArM
- Obtain DrugBank MOA data to strengthen the mechanistic rationale
- Await completion and results of NCT07237763
- Confirm drug-drug interaction (DDI) profile, particularly given ketoconazole's known CYP3A4 inhibition
- Clarify German/EU marketing authorization status for this compound and formulation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.